ReviewEuropean respiratory review : an official journal of the European Respiratory Society2013
Smoking cessation and COPD.
Review in European respiratory review : an official journal of the European Respiratory Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 81 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An 8-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CHF 718 pMDI (HFA Beclomethasone Dipropionate Via Pressured Metered Dose Inhaler) in Asthmatic Subjects.
A 6-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 5259 pMDI (HFA Glycopyrronium Bromide Via Pressurized Metered Dose Inhaler) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI (Formoterol Fumarate) in Asthmatic Subjects
A Randomized Open-label, Superiority, Multicenter, Two-arm Intervention Study of the Effect of "High-intensity" vs. 'Low-intensity' Smoking Cessation Intervention in Active Smokers With COPD
Who cites it
81 citing papers in PubMed, 4 syntheses or guidelines pooled it, 182 citations in OpenAlex.
- Lung function improvement following smoking cessation in chronic respiratory conditions: A meta-analytic approach.The Journal of international medical research · 2025Pooled it
- Pharmacological interventions on smoking cessation: A systematic review and network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Pooled it
- Pooled it
- Identifying patients with mild-to-moderate COPD who require intensified initial treatment to control annualized clinically important deterioration.NPJ primary care respiratory medicine · 2026Trial
- The Role of Melatonin in Smoking Cessation and COPD Management: A Randomized Controlled Trial.Canadian respiratory journal · 2026Trial
- The Effect of Albuterol Spray on Hypoxia and Bronchospasm in Patients with Chronic Obstructive Pulmonary Disease (COPD) under General Anesthesia: A bouble-Blind Randomized Clinical Trial.Ethiopian journal of health sciences · 2023Trial
- Trial
- A pilot randomized controlled trial of smoking cessation in an outpatient respirology clinic.Canadian respiratory journalTrial
- E-cigarette use among individuals with chronic obstructive pulmonary disease.Internal and emergency medicine · 2026Article
- E-cigarette switching in COPD: reduced cardiovascular events without improvement in respiratory outcomes.Respiratory research · 2026Article
- The Prevalence of Emphysema in Patients Undergoing Lung Cancer Screening in a Middle-Income Country.Diseases (Basel, Switzerland) · 2025Article
- Smoking cessation improves health status of patients with chronic diseases: evidence from a longitudinal study of older adults in China.BMC public health · 2025Article
- Elucidating the Relationship Between Body Fat Index and Pulmonary Health: Insights from Cross-Sectional Analysis and Mendelian Randomization.International journal of chronic obstructive pulmonary disease · 2025Article
- A window of opportunity: a pilot study exploring smoking cessation support during COPD hospitalisation.Frontiers in health services · 2025Article
- Article
- The uphill journey of smoking cessation in chronic obstructive pulmonary disease: why a well-built vehicle matters.Frontiers in health services · 2025Review
- The role of nurses in smoking cessation interventions for patients: a scoping review.BMC nursing · 2024Article
- Association of monoaminergic gene polymorphisms in chronic inflammatory pulmonary disease patients with successful smoking cessation.BMC pulmonary medicine · 2024Article
- Prevalence of nicotine dependence among smokers aged 40 years and older in China.Chinese medical journal pulmonary and critical care medicine · 2024Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mainstay in smoking cessation is counselling in combination with varenicline, nicotine replacement therapy (NRT) or bupropion SR. Varenicline and combination of two NRTs is equally effective, while varenicline alone is more effective than either NRT or bupropion SR. NRT is extremely safe but cardiovascular and psychiatric adverse events with varenicline have been reported. These treatments have also been shown to be effective in patients with chronic obstructive pulmonary disease (COPD). A model study is the Lung Health Study from the USA. Findings from this study of 5,587 patients with mild COPD showed that repeated smoking cessation for a period of 5 yrs resulted in a quit rate of 37%. After 14.5 yrs the quitters had a higher lung function and a higher survival rate. A study with a new nicotine formulation, a mouth spray, showed high relative efficacy. As 5-10% of quitters use long-term NRT, we report the results of a study where varenicline compared with placebo increased the quit rate in long-term users of NRT. Smoking cessation is the most effective intervention in stopping the progression of COPD, as well as increasing survival and reducing morbidity. This is why smoking cessation should be the top priority in the treatment of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.